Besides local resection, external radiation therapy (EXRT) plays the major role in the treatment of malignant glioma. With postoperative EXRT, median survival is increased to 9-12 months for glioblastoma multiforme (GBM), as compared to 4-5 months after surgery alone (median survival for anaplastic astrocytoma (AA): 27 months – 3 years). The target volume should include 2 cm beyond that indicated by CT and MRI. For treatment planning computed tomography in treatment position is mandatory, and an individualized face mask for immobilization of the head should be used during the whole process of treatment planning and treatment delivery. With conventional fractionation, a total dose of 60 Gy seems to be adequate. There is no evidence that the application of higher total doses, of hyperfractionated XRT, of radiosensitizers or of fast neutron radiotherapy can improve treatment results. The role of high precision single-dose stereotactic irradiation and of brachytherapy is undefined. For both techniques, it seems difficult to control AA or GBM at the perimeter of the tumor which is a frequent site of failure. The use of the chlorethyl nitrosoureas (e.g. BCNU, ACNU) is the most effective and frequent form of chemotherapy for malignant glioma. Adding chemotherapy to postoperative radiotherapy leads to an increased percentage of 18-month survivors, but the improvement of median survival for the whole group of patients is within several weeks. Prognostic factors such as grade, performance status, and age may considerably influence treatment results and treatment strategies. In severely compromised patients, treatment time may be reduced by altered fractionation schemes, and chemotherapy seems to be debatable.

Keywords:
Malignant glioma, Radiotherapy, Radiosensitizers, Chemotherapy, Prognostic factors, Quality of life
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.